We use cookies for certain features and to improve your experience. See our Cookie Policy and Privacy Policy to learn more

Leafly

Shop legal, local weed.

Open
advertise on Leafly
ShopDeliveryDispensariesDealsStrainsBrandsProductsCBDDoctorsCannabis 101Social impact
  • Sign in
  • Create account
  • Strains
  • Shop
  • Shop
  • Delivery
  • Deals
  • Dispensaries
  • CBD Stores
  • Brands
  • Products
  • Learn
  • Cannabis 101
  • News
  • Leafly Learn
  • Science of cannabis
  • Doctors
  • Social impact
  • Lab partners
  • Download the Leafly App
  • Advertise on Leafly
    • Leafly.comUSA flag
    • Leafly.caCanadian flag
    • Leafly.deGerman flag
  • Help
  • News
  • Lifestyle
  • Strains & products
  • Industry
  • Growing
  • Health
  • Science & tech
  • Leafly USA
  • Podcasts
  • Learn
CanadaIndustry

Marlboro Maker Investing $2.4 Billion in Canadian Cannabis Producer Cronos

Leafly Canada StaffPublished on December 7, 2018 · Last updated July 28, 2020
Cronos
1001Love/iStock

Canadian cannabis producer Cronos Group announced Friday that it will receive a $2.4 billion equity investment from Altria Group, the maker of Marlboro cigarettes.Explore the World’s Largest Strain DatabaseCronos had previously confirmed reports that it was in talks with Altria, which joins Molson Coors, Constellation Brands, and other established companies that are making moves in the cannabis space.

For its initial investment, the tobacco giant will acquire a 45% ownership stake in Cronos. The arrangement also allows for Altria to invest up to a further $1.4 billion to increase its ownership stake in Cronos to 55%.

“Altria is the ideal partner for Cronos Group, providing the resources and expertise we need to meaningfully accelerate our strategic growth,” said Mike Gorenstein, Cronos Group Chairman, President, and Chief Executive Officer. “The proceeds from Altria’s investment will enable us to more quickly expand our global infrastructure and distribution footprint, while also increasing investments in R&D and brands that resonate with our consumers.”

According to a news release, Altria’s resources will better position the Cronos Group “to support cannabinoid innovation, create differentiated products and brands across medicinal and recreational categories, and expand its global footprint and growing production capacity.”

The deal will leverage Altria’s decades of experience navigating the complex regulatory landscape, government affairs, compliance, and brand management. Tapping into Altria’s expertise in product development, Chronos also expects to expand its product offerings including device technologies such as cannabis vape products, as regulations permit.

With files from The Canadian Press.

Shop highly rated dispensaries near you

Showing you dispensaries near
See all dispensaries
  • Loading...
    Loading...Loading...
    Loading...
    Loading...Loading...
    Loading...Loading...
  • Loading...
    Loading...Loading...
    Loading...
    Loading...Loading...
    Loading...Loading...
  • Loading...
    Loading...Loading...
    Loading...
    Loading...Loading...
    Loading...Loading...
  • Loading...
    Loading...Loading...
    Loading...
    Loading...Loading...
    Loading...Loading...
  • See all dispensaries
See all dispensaries
CanadainvestingLicensed Producers
Leafly Canada Staff
Leafly Canada Staff
Leafly Canada is based in Toronto, with correspondents and contributors stretching from Newfoundland to BC. To reach our editorial staff please contact us at info@leafly.com.
View Leafly Canada Staff's articles

The latest in Canada

  • Vancouver weed visitor’s guide 2024 image
    Vancouver weed visitor’s guide 2024
    Amelia Williams
  • A history of cannabis prohibition in Canada image
    A history of cannabis prohibition in Canada
    Emma Spears
  • Are psychedelics legal in Canada? image
    Are psychedelics legal in Canada?
    Colleen Fisher Tully
  • D8, Eh? What Canadians need to know about Delta-8 cannabis products image
    D8, Eh? What Canadians need to know about Delta-8 cannabis products
    Adam Greenblatt
Get good reads, local deals, and strain spotlights delivered right to your inbox.

By providing us with your email address, you agree to Leafly's Terms of Service and Privacy Policy.



Stay In Touch

Receive updates on new products, special offers, and industry news.

Something went wrong, please try again.

By providing us with your email address, you agree to Leafly’s Terms of Service and Privacy Policy.

Leafly mobile app
Get high for less.
Download the Leafly app.
Download Leafly: Marijuana Reviews on the App StoreDownload Leafly Marijuana Reviews on Google Play

Business Solutions
  • List your store
  • List your CBD store
  • List your brand
  • List your practice
  • Business log in

About Leafly
  • About us
  • Careers
  • Newsroom
  • Investor relations
  • Contact us
  • FAQs
  • Accessibility

Dispensaries in
  • Los Angeles
  • Seattle
  • Portland
  • San Francisco
  • Toronto
  • Detroit

Privacy & Terms
  • Terms of use
  • Commercial terms of use
  • Privacy policy
  • Do not sell my personal information

* Statements made on this website have not been evaluated by the U.S. Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease. Information provided by this website or this company is not a substitute for individual medical advice.


© 2025 Leafly, LLC
Leafly and the Leafly logo are registered trademarks of Leafly, LLC. All Rights Reserved.